BridgeBio Pharma, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO) with Eidos Therapeutics, Inc. (“Eidos”) (NASDAQ: EIDX). Under the terms of the merger, BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of Eidos’ outstanding shares. Eidos stockholders will have the right to receive in the transaction, at their election, either 1.85 shares of BridgeBio common stock or $73.26 in cash per Eidos share in the transaction.

The BridgeBio merger investigation concerns whether the Board of BridgeBio has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.